Ascendis Pharma A/S (ASND) shareholders
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$275.39+8.32 (+3.12%)
Close on Nov 13, 2026Market cap $17.07BP/E 22.4Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
67M of 62M shares
Institutional holders
311
90 new, 51 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
9 buys · 3 sales
Net sold $4.74M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (16.10%), Peter Kolchinsky (16.10%) and 1 more | 9,710,428 | 16.10% | 13G (passive) amendment | Sep 30, 2024 |
| T. Rowe Price Investment Management, Inc. | 6,506,219 | 10.50% | 13G (passive) amendment | Apr 30, 2026 |
| Westfield Capital Management Company, L.P. | 5,185,696 | 8.48% | 13G (passive) amendment | Dec 31, 2025 |
| Behzad Aghazadeh Joint filing with Avoro Capital Advisors LLC (8.20%) | 4,988,888 | 8.20% | 13G (passive) amendment | Sep 30, 2024 |
| Abigail P. Johnson Joint filing with FMR LLC (6.60%) | 3,852,101 | 6.60% | 13G (passive) amendment | Mar 31, 2026 |
| Janus Henderson Group PLC | 3,719,452 | 6.00% | 13G (passive) amendment | Mar 31, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (5.20%) | 3,425,993 | 5.20% | 13G (passive) amendment | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ASND | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 10,281,496 | 16.59% | $2.74B | – | 23.83% |
| T. Rowe Price Investment Management, Inc. | 6,754,846 | 10.90% | $1.80B | +592,804 | 1.18% |
| Avoro Capital Advisors LLC | 5,111,111 | 8.25% | $1.36B | +48,611 | 12.24% |
| Westfield Capital Management Co LP | 4,798,267 | 7.74% | $1.28B | −15,173 | 4.18% |
| Jupiter Topco LLC | 3,648,772 | 5.89% | $973.38M | New | 0.40% |
| FMR LLC | 3,545,575 | 5.72% | $945.68M | −331,026 | 0.04% |
| Artisan Partners Limited Partnership | 2,634,024 | 4.25% | $702.55M | −596,164 | 1.11% |
| BlackRock, Inc. | 2,211,833 | 3.57% | $589.94M | +1,550,779 | 0.01% |
| Capital International Investors | 1,988,614 | 3.21% | $530.40M | +29,771 | 0.11% |
| Massachusetts Financial Services Co /Ma/ | 1,875,301 | 3.03% | $500.14M | +14,632 | 0.16% |
| Franklin Resources Inc | 1,862,503 | 3.01% | $496.77M | −189,445 | 0.11% |
| Wellington Management Group Llp | 1,548,636 | 2.50% | $413.05M | −208,997 | 0.07% |
| American Century Companies Inc | 1,400,575 | 2.26% | $373.56M | +3,456 | 0.17% |
| Perceptive Advisors LLC | 1,163,721 | 1.88% | $310.39M | −367,700 | 4.66% |
| Price T Rowe Associates Inc /Md/ | 1,122,529 | 1.81% | $299.40M | −407,816 | 0.03% |
| Capital World Investors | 906,081 | 1.46% | $241.67M | +5,564 | 0.03% |
| Principal Financial Group Inc | 873,502 | 1.41% | $232.98M | −22,895 | 0.11% |
| Polar Capital Holdings Plc | 616,908 | 1.00% | $164.54M | −34,804 | 0.39% |
| Goldman Sachs Group Inc | 559,534 | 0.90% | $149.24M | −6,658 | 0.01% |
| Morgan Stanley | 544,393 | 0.88% | $145.20M | −61,955 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 311 | 67M | 100.0% | 90 / 100 | 94 / 51 | 10M | 6M |
| Q1 2026 | 274 | 63M | 100.0% | 34 / 109 | 106 / 60 | 7M | 11M |
| Q4 2025 | 303 | 66M | 100.0% | 62 / 120 | 92 / 36 | 6M | 5M |
| Q3 2025 | 279 | 64M | 100.0% | 56 / 99 | 92 / 22 | 6M | 5M |
| Q2 2025 | 247 | 63M | 100.0% | 44 / 81 | 89 / 40 | 4M | 7M |
| Q1 2025 | 244 | 65M | 100.0% | 54 / 78 | 88 / 23 | 5M | 3M |
| Q4 2024 | 214 | 64M | 100.0% | 37 / 85 | 66 / 39 | 6M | 5M |
| Q3 2024 | 219 | 63M | 100.0% | 43 / 78 | 69 / 25 | 9M | 7M |
| Q2 2024 | 203 | 61M | 98.0% | 38 / 74 | 68 / 23 | 6M | 6M |
| Q1 2024 | 189 | 61M | 98.6% | 39 / 74 | 50 / 33 | 6M | 4M |
| Q4 2023 | 185 | 60M | 97.5% | 47 / 53 | 65 / 21 | 4M | 4M |
| Q3 2023 | 160 | 60M | 97.3% | 19 / 53 | 63 / 15 | 2M | 2M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mads Bodenhoff | SVP & PAO | 0 | – | Sep 9, 2026 |
| Scott Thomas Smith | EVP & Chief Financial Officer | 4,367 | 0.01% | Jun 2, 2026 |
| Flemming Steen Jensen | See Remarks | 0 | – | May 12, 2026 |
| Kennett Sprogoe | See Remarks | 19,570 | 0.03% | Mar 18, 2026 |
| Aimee Shu | EVP & Chief Medical Officer | 0 | – | Mar 18, 2026 |
| Jay Donovan Wu | EVP & President US Market | 1,068 | 0.00% | Mar 18, 2026 |
| Michael Wolff Jensen | EVP, Chief Legal Officer | – | – | Mar 18, 2026 |
| Anni Lotte Kirstine Sonderbjerg Pedersen | EVP & Chief Admin Officer | 19,460 | 0.03% | Mar 18, 2026 |
| Jean Jacques Bienaime | Director | 2,900 | 0.00% | Sep 28, 2026 |
| Lars Holtug | Director | 4,000 | 0.01% | Sep 3, 2026 |
| Albert Cha | Director | 3,730 | 0.01% | Mar 18, 2026 |
| Siham Imani | Director | 2,317 | 0.00% | Mar 18, 2026 |
| Jan Moller Mikkelsen | Director | 453,403 | 0.73% | Mar 18, 2026 |
| William Fairey | Director | 2,117 | 0.00% | Mar 18, 2026 |
| Lisa Morrison | Director | 1,572 | 0.00% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mads Bodenhoff SVP & PAO | Sep 8, 2026 | Sale | −3,000 | $270.19 | $810.57K | 0 |
| Mads Bodenhoff SVP & PAO | Sep 8, 2026 | Option exercise | +3,000 | $110.00 | $330.00K | 3,000 |
| Lars Holtug Director | Sep 2, 2026 | Sale | −236 | $264.13 | $62.33K | 4,000 |
| Jean Jacques Bienaime Director | Aug 14, 2026 | Buy | +900 | $246.91 | $222.22K | 2,900 |
| Jean Jacques Bienaime Director | Aug 14, 2026 | Buy | +1,100 | $245.85 | $270.44K | 2,000 |
| Scott Thomas Smith EVP & Chief Financial Officer | Jun 2, 2026 | Buy | +100 | $219.00 | $21.90K | 4,367 |
| Scott Thomas Smith EVP & Chief Financial Officer | May 29, 2026 | Buy | +250 | $223.32 | $55.83K | 4,267 |
| Jean Jacques Bienaime Director | May 29, 2026 | Buy | +200 | $222.30 | $44.46K | 800 |
| Jean Jacques Bienaime Director | May 29, 2026 | Buy | +100 | $223.50 | $22.35K | 900 |
| Jean Jacques Bienaime Director | May 29, 2026 | Buy | +200 | $223.76 | $44.75K | 600 |
| Jean Jacques Bienaime Director | May 26, 2026 | Buy | +200 | $236.24 | $47.25K | 200 |
| Jean Jacques Bienaime Director | May 26, 2026 | Buy | +200 | $239.37 | $47.87K | 400 |
| Flemming Steen Jensen See Remarks | May 11, 2026 | Sale | −19,460 | $238.49 | $4.64M | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
3M shares short
Days to cover
5.0
At 1M shares a day
Change since last report
-4.3%
From 3M shares
Short volume, 20 days
55.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ascendis Pharma A/S's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,201 shares on Oct 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mads Bodenhoff Officer | Sep 8, 2026 | 3,000 | $810.56K | Sep 8, 2026 | Warrant exercise |
| Lars Holtug Director | Sep 2, 2026 | 236 | $62.33K | Sep 2, 2026 | SHARE PLAN ACCOUNT |
| Flemming Steen Jensen Officer, EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY | May 11, 2026 | 19,460 | $4.64M | May 11, 2026 | SHARE PLAN ACCOUNT |
| Singel Stina Officer | Mar 9, 2026 | 3,782 | $907.68K | Mar 9, 2026 | Warrant exercise |
| Scott Thomas Smith Officer | Mar 6, 2026 | 10,000 | $2.40M | Mar 5, 2026 | Warrant exercise |
| Mads Bodenhoff Officer | Mar 6, 2026 | 10,000 | $2.38M | Mar 6, 2026 | Warrant exercise |
| Jan Moller Mikkelsen CEO, Officer | Mar 5, 2026 | 94,000 | $22.69M | Mar 5, 2026 | Warrant Exercise |
| Scott Thomas Smith Officer | Mar 5, 2026 | 10,000 | $2.40M | Mar 5, 2026 | Warrant exercise |
| Aimee Shu Officer | Mar 5, 2026 | 5,583 | $1.32M | Mar 5, 2026 | Warrant exercise |
| Lisa Morrison Officer | Mar 4, 2026 | 10,105 | $2.39M | Mar 4, 2026 | Warrant exercise |
| Aimee Shu Officer, EXECUTIVE VICE PRESIDENT CHIEF MEDICAL OFFICER | Mar 4, 2026 | 7,290 | $1.74M | Mar 4, 2026 | SHARE PLAN ACCOUNT |
| William Fairey Director | Mar 2, 2026 | 1,800 | $435.76K | Mar 2, 2026 | RESTRICTED STOCK VESTING |
| Siham Imani Director | Mar 2, 2026 | 1,800 | $435.76K | Mar 2, 2026 | RESTRICTED STOCK VESTING |
| Scott Thomas Smith Officer, EXECUTIVE VP CHIEF FINANCIAL OFFICER | Mar 2, 2026 | 18,349 | $4.44M | Mar 2, 2026 | RESTRICTED STOCK VESTING |
| Michael Wolff Jensen Officer, EXECUTUVE VP CHIEF LEGAL OFFICER | Mar 2, 2026 | 18,349 | $4.44M | Mar 2, 2026 | RESTRICTED STOCK VESTING |
See a number that looks wrong?